



Curriculum Vitae

Personal information **Panagiota Tsantili**

Work experience

1. Employer: National Organization for Medicines
 - Start date: 06-2009
 - End date:
 - Position: Assessor, Section of Biological Products, Evaluation Division
 - Activities: Quality, Non_Clinical and Clinical assessor of biological products [Biologicals of recDNA origin, Neurotoxins, Blood products (Coagulation factors, Intravenous Immunoglobulins), Vaccines].
 - Scientific Board of approvals for Biological products (national applications): Scientific Secretary (October 2018_present) Biosimilar Medicinal Products Working Party (BMWP) Observer Appointment: October 2010 - present.
 - Biologics Working Party (BWP) Alternate member: June 2014 - present.
 - HMA, Biosimilar Working Group (BSWG) Member : Sept. 2021- present
 - Country: Greece
2. Employer: Ministry of Health and Social Solidarity
 - Start date: 10-2006
 - End date: 06-2009
 - Position: Division of Medicines and Pharmacies
 - Activities: Pharmacist, Section of Opioid Analgesics
 - Country: Greece
3. Employer: Technological Educational Institute of Athens (TEI), Dept. of Medical Laboratories.
 - Start date: 09-2003
 - End date: 06-2005
 - Position: Teaching position, (Associate Professor level)
 - Activities: Course in Biology
 - Country: Greece
4. Employer: Massachusetts General Hospital_Harvard Medical School, Dept. of Surgery, Antibody Engineering Laboratory _ Boston, MA
 - Start date: 02-2000
 - End date: 11-2001
 - Position: Post_Doctoral Research Fellow.
 - Activities: Refinement of recombinant antibody structure for immunotherapy. Insertional mutagenesis in CDR loops to modify the specificity of antidigoxin Fab fragments. Identification of antigenic epitopes of Streptokinase (SK).
 - Country: United States
5. Employer: Boston University School of Medicine, Section of Molecular Genetics, Cardiovascular Institute, Boston, MA
 - Start date: 04-1998
 - End date: 01-2000
 - Position: Post_Doctoral Research Fellow
 - Activities: Structure_function analysis of the transcription activation domains of Hepatocyte Nuclear Factor 4
 - Country: United States

Education and training

1. National & Kapodistrian University of Athens, Department of Biology
 - Start date: 08-1993
 - End date: 04-1998
 - Qualification: Ph.D. Degree
 - Ph.D. thesis title: "Recombinant Monoclonal Antibodies against the Acetylcholine Receptor". Molecular mechanisms of autoimmunity, pathophysiology of Myasthenia Gravis, generation and biological characterization of recombinant mAb fragments, structural analysis of mAbs for receptor binding, AChR receptor_mAb interactions
 - Country: Greece
2. Aristotle University of Thessaloniki, Department of Chemistry, Section of Biochemistry.
 - Start date: 07-1991
 - End date: 10-1992
 - Qualification: Research Assistant
 - Project title: "Establishment of Assay Conditions for Human Pancreatic Lipase". Lipase activity determination, enzyme purification techniques.
 - Country: Greece
3. Aristotle University of Thessaloniki, Department of Pharmacy.
 - Start date: 09-1987
 - End date: 07-1991
 - Qualification: Bachelor Degree in Pharmacy
 - Country: Greece

TRAINING

1. Subject: BMWP/BWP joint assessors training on assessment of similar biological medicinal products containing monoclonal antibodies
 - Start date: 10-2012

- Qualification: Training
 - Organisation: EMA
 - Country: United Kingdom
2. Subject: Dendrimers as Composites of Advanced Drug Delivery nano Systems (aDDnSs): Biomedical Applications
 - Start date: 10-2011
 - Qualification: Training School and workshop
 - Organisation: National and Kapodistrian University of Athens, Dept. of Pharmacy, National Research Foundation, Athens
 - Country: Greece
 3. Subject: Blood Products Assessors training (BPWP) Webinar
 - Start date: 09-2011
 - Qualification: Training
 - Organisation: EMA
 - Country: United Kingdom
 4. Subject: Assessor's Training on Advance Therapy Medicinal Products
 - Start date: 04-2011
 - Qualification: Training
 - Organisation: EMA
 - Country: United Kingdom
 5. Subject: Common Assessment Framework: Total Quality Management Tool
 - Start date: 03-2011
 - Qualification: Training
 - Organisation: National Centre for Public Administration & Local Government (E.K.D.D.A.), Athens
 - Country: Greece
 6. Subject: FEBS "ADVANCED COURSE ON GENE THERAPY"
 - Start date: 10-1995
 - Qualification: Training
 - Organisation: FEBS course
 - Country: Varena, Italy
 7. Subject: Advanced Study Course "MOLECULAR MECHANISMS OF TRANSCELLULAR SIGNALLING: From the Membrane to the Gene.
 - Start date: 08-1994
 - Qualification: Training
 - Organisation: "FEBS/NATO Summer School,
 - Country: Spetsai, Greece

Additional information

Publications

1. Kurki P, Barry S, Bourges I, Tsantili P, Wolff_Holz E. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. *Drugs*. 2021 Oct 1. doi: 10.1007/s40265_021_01601_2
2. Aggelidou E, Iordanidou P, Tsantili P, Papadopoulos G, Hadzopoulou_Cladaras M. Critical role of residues defining the ligand binding pocket in hepatocyte nuclear factor_4a (HNF_4a). *J Biol Chem*. 2004 Jul 16; 279 (29): 30680_8.
3. Parhami_Seren B, Seavey M, Krudysz J, Tsantili P. Structural correlates of a functional streptokinase antigenic epitope: serine 138 is an essential residue for antibody binding. *J Immunol Methods*. 2003 Jan 15;272(1_2):93_105.
4. Krykbaev RA, Tsantili P, Jeffrey PD, Margolies MN. Modifying specificity of antidigoxin antibodies using insertional mutagenesis. *Protein Sci*. 2002 Dec;11 (12):2899_908.
5. Hadzopoulou_Cladaras M, Aggelidou E, Iordanidou P, Tsantili P. Mutations in the ligand binding domain (LBD) of hepatocyte nuclear factor 4 alpha (HNF_4 alpha) affect transcriptional activation and coactivator interaction. *Circulation*, Nov. 5 2002;106 (19): 832 Supplement
6. Parhami_Seren B, Krudysz J, Tsantili P. Affinity panning of peptide libraries using anti_streptokinase monoclonal antibodies: selection of an inhibitor of plasmin(ogen) active site. *J Immunol Methods*. 2002 Sep 15;267(2):185.
7. Kardassis D, Falvey E, Tsantili P, Hadzopoulou_Cladaras M, Zannis V. Direct physical interactions between SP1 and HNF_4 mediate synergistic transactivation of the Apolipoprotein C III promoter. *Biochemistry*. 2002 Jan 29;41(4):1217_28.
8. Kistanova E, Dell H, Tsantili P, Falvey E, Cladaras C, Hadzopoulou_Cladaras M. The AF_1 domain of HNF_4 is an acidic activator that mediates interactions through bulky hydrophobic residues. *Biochem. J*, 2001;356:635_42.
- 9*. Poulas K, Tsibri E, Kokla A, Papanastasiou D, Tsouloufis T, Marinou M, Tsantili P, Papapetropoulos T, Tzartos SJ. Epidemiology of myasthenia gravis in Greece. *J of Neurol Neurosurg Psychiatry* 2001;71:352_56.
10. Kardassis D, Falvey E, Tsantili P, Hadzopoulou_Cladaras M, Zannis V. Direct physical interactions between SP1 and HNF_4 mediate synergistic transactivation of the Apolipoprotein CIII promoter. *Circulation*, Oct 31 2000; 102 (18): 1440 Supplement
11. Kontou M, Leonidas DD, Vatzaki EH, Tsantili P, Mamalaki A, Oikonomakos NG, Acharya KR, Tzartos SJ. The crystal structure of the Fab fragment of a rat monoclonal antibody against the main immunogenic region of the human muscle acetylcholine receptor. *Eur J Biochem*. 2000;267(8):2389_97.
12. Poulas K, Tsibri E, Papanastasiou D, Tsouloufis T, Marinou M, Tsantili P, Papapetropoulos T, Tzartos SJ. Equal male and female incidence of myasthenia gravis. *Neurology*. 2000;54(5):1202_3.
13. Tsantili P, Tzartos SJ, Mamalaki A. High affinity antibody fragments protecting the human nicotinic acetylcholine receptor. *J. Neuroimmunol* 1999;94:15_28.
14. Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, Papanastasiou D, Sakarellos C, Sakarellos_Daitsiotis M, Tsantili P, Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle_type nicotinic acetylcholine receptor. *Immunol Rev*. 1998 Jun;163:89_120
15. Tzartos SJ, Tsantili P, Papanastasiou D, Mamalaki A. Construction of single_chain Fv fragments of anti_MIR monoclonal antibodies. *Ann N Y Acad Sci*. 1998;841:475_7.
16. Tsantili P., Mamalaki A. and Tzartos S Construction of a single chain Fv antibody (scFv195) fragment against the human Acetylcholine receptor. Contribution of light chain amino acid residues in receptor recognition". *Immunology Letters* 1997 May; 56 (Part 2).
17. Tzartos SJ, Cung MT, Mamalaki A, Marraud M, Papanastasiou D, Sakarellos C, Sakarellos_Daitsiotis M, Tsantili P. Antigenic structure of the muscle nicotinic acetylcholine receptor. *Ann Med Interne*. 1996, 147(6):442_6
18. Arzoglou P, Goudoula C, Tsantili P, Lessinger JM, Ferard G, Mignot V, Samyn N, Demeester J, Lauwers A,

Brettschneider H, et al. Transferability of lipase titrimetric assays: deductions from an interlaboratory study. Eur J Clin Chem Clin Biochem 1994;32(10):773_7

* Authors of the manuscript are recipients of Honorary Award from National and Kapodistrian University of Athens.

Projects

Memberships

Other Relevant Information

LANGUAGES: GREEK (native speaker) OTHER LANGUAGES: ENGLISH Excellent (reading, writing and verbal skills)